[HTML][HTML] Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies

P Zhou, H Wang, M Fang, Y Li, H Wang, S Shi… - PLoS …, 2019 - journals.plos.org
P Zhou, H Wang, M Fang, Y Li, H Wang, S Shi, Z Li, J Wu, X Han, X Shi, H Shang, T Zhou
PLoS pathogens, 2019journals.plos.org
Recently identified broadly neutralizing antibodies (bnAbs) show great potential for clinical
interventions against HIV-1 infection. However, resistant strains may impose substantial
challenges. Here, we report on the identification and characterization of a panel of HIV-1
strains with broad and potent resistance against a large number of bnAbs, particularly those
targeting the CD4-binding site (CD4bs). Site-directed mutagenesis revealed that several key
epitope mutations facilitate resistance and are located in the inner domain, loop D, and …
Recently identified broadly neutralizing antibodies (bnAbs) show great potential for clinical interventions against HIV-1 infection. However, resistant strains may impose substantial challenges. Here, we report on the identification and characterization of a panel of HIV-1 strains with broad and potent resistance against a large number of bnAbs, particularly those targeting the CD4-binding site (CD4bs). Site-directed mutagenesis revealed that several key epitope mutations facilitate resistance and are located in the inner domain, loop D, and β23/loop V5/β24 of HIV-1 gp120. The resistance is largely correlated with binding affinity of antibodies to the envelope trimers expressed on the cell surface. Our results therefore demonstrate the existence of broadly resistant HIV-1 strains against CD4bs neutralizing antibodies. Treatment strategies based on the CD4bs bnAbs must overcome such resistance to achieve optimal clinical outcomes.
PLOS